IONS
Ionis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$58.09
−0.07%Year over year
Reported trailing growth
- Revenue
- -9.6%
- EBITDA
- +2919.0%
- EBIT
- —
- EPS
- —
- Free cash flow
- -84.7%
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +6.9%
- EBITDA
- —
- EPS
- -14.8%
Three-year CAGR
- Revenue
- +17.1%
- EBITDA
- +18.9%
- EBIT
- +19.6%
- Net income
- +16.1%
- EPS
- +21.7%
- Free cash flow
- +41.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026